25 completed, 11 terminated, 7 recruiting, 4 active not recruiting. 28 Phase 2, 25 Phase 1, 9 Phase 3.
Follow Arrowhead Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia Zodasiran - Homozygous Familial Hypercholesterolemia | Phase 3 | Recruiting | Arrowhead Pharmaceuticals | 10 | 2026-10-01 | 2026-10-26 |
| A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis ARO-INHBE, Placebo - Metabolic Dysfunction-Associated Steatohepatitis | Phase 2 | Not yet recruiting | Arrowhead Pharmaceuticals | 252 | 2026-09-01 | 2026-10-06 |
| A First-In-Human Study of ARO-033 in Adult Participants ARO-033, Placebo - Age-related Macular Degeneration | Phase 1 | Recruiting | Arrowhead Pharmaceuticals | 84 | 2026-06-25 | 2026-09-15 |
| Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma ARO-RAGE, Placebo - Asthma | Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 36 | 2026-03-30 | 2026-10-01 |
| Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia ARO-DIMERPA, Placebo - Hyperlipidemia; Mixed | Phase 1 / Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 78 | 2025-12-22 | 2026-10-13 |
| Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease ARO-MAPT-SC, Placebo - Alzheimer Disease, Alzheimer Disease, Early Onset | Phase 1 / Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 112 | 2025-11-18 | 2026-09-18 |
| A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) zodasiran Injection, Placebo - Homozygous Familial Hypercholesterolemia | Phase 3 | Active not recruiting | Arrowhead Pharmaceuticals | 70 | 2025-06-17 | 2026-08-12 |
| A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus ARO-ALK7, Placebo - Obesity, Diabetes Mellitus, Type 2 | Phase 1 / Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 150 | 2025-05-09 | 2026-07-08 |
| Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis Plozasiran, Placebo - Severe Hypertriglyceridemia | Phase 3 | Recruiting | Arrowhead Pharmaceuticals | 288 | 2025-04-24 | 2026-09-21 |
| Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia Plozasiran Injection - Hypertriglyceridemia | Phase 3 | Active not recruiting | Arrowhead Pharmaceuticals | 710 | 2025-04-09 | 2026-10-01 |
| Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 ARO-ATXN2 Injection, Placebo - Spinocerebellar Ataxia Type 2 | Phase 1 | Active not recruiting | Arrowhead Pharmaceuticals | 39 | 2024-12-17 | 2026-06-29 |
| A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus ARO-INHBE, Placebo, Tirzepatide - Obesity | Phase 1 / Phase 2 | Active not recruiting | Arrowhead Pharmaceuticals | 190 | 2024-12-04 | 2026-10-30 |
| Study of Plozasiran in Adults With Severe Hypertriglyceridemia Plozasiran Injection, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 311 | 2024-07-23 | 2026-10-09 |
| Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia Plozasiran Injection, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 446 | 2024-07-22 | 2026-10-08 |
| Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia Plozasiran Injection, Placebo - Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 1456 | 2024-05-21 | 2026-09-25 |
| Study of ARO-CFB in Adult Healthy Volunteers ARO-CFB, Placebo - IgA Nephropathy | Phase 1 | Completed | Arrowhead Pharmaceuticals | 49 | 2024-04-05 | 2026-05-20 |
| Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) ARO-SOD1 Injection - Amyotrophic Lateral Sclerosis | Phase 1 | Withdrawn | Arrowhead Pharmaceuticals | 2024-01-01 | 2024-04-17 | |
| A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome Plozasiran, Placebon - Familial Chylomicronemia Syndrome | Phase 3 | Completed | Visirna Therapeutics HK Limited | 37 | 2023-07-10 | 2026-02-27 |
| Study of VSA001 Injection in Chinese Healthy Adult Volunteers VSA001 injection, Placebo - Healthy Adult Volunteers | Phase 1 | Completed | Visirna Therapeutics HK Limited | 24 | 2023-05-17 | 2025-03-20 |
| Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis ARO-MMP7 Inhalation Solution, Placebo - Idiopathic Pulmonary Fibrosis | Phase 1 / Phase 2 | Completed | Arrowhead Pharmaceuticals | 105 | 2023-01-30 | 2026-08-05 |
Showing 20 of 52. Sign in to see all of them.
Hepatitis B (8) · Hypertriglyceridemia (8) · alpha 1-Antitrypsin Deficiency (5) · Asthma (4) · Dyslipidemias (3) · Hepatitis B, Chronic (3) · Homozygous Familial Hypercholesterolemia (3) · Hyperlipoproteinemia Type I (3) · Hyperlipoproteinemia Type II (3) · Glomerulonephritis, IGA (2) · Obesity (2) · Alzheimer Disease (1) · Amyotrophic Lateral Sclerosis (1) · Carcinoma, Renal Cell (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)
ARC-520 (9) · plozasiran (9) · entecavir (7) · Tenofovir (6) · Histamine Antagonists (5) · Diphenhydramine (3) · zodasiran (2) · Acetaminophen (1) · Cetirizine (1) · Chlorpheniramine (1) · JNJ-56136379 (1) · Saline Solution (1) · Sodium Chloride (1) · Tirzepatide (1) · peginterferon alfa-2a (1)
New Zealand (28) · Australia (26) · Canada (19) · United States (17) · Germany (14) · Poland (11) · Spain (11) · China (9) · South Korea (9) · United Kingdom (9) · Hungary (8) · Italy (7) · Argentina (6) · Bulgaria (6) · Czechia (6)
Bruce Given, MD (1) · Jason Lickliter, MD, PhD (1)
PMID 38682459, PMID 29572094, PMID 33712437, PMID 33900278, PMID 34256305, PMID 35695169, PMID 35748699, PMID 35870702, PMID 36513186, PMID 37626170, PMID 38299639, PMID 38320498, PMID 38583092, PMID 38804517, PMID 38809174, PMID 38964420, PMID 39225259, PMID 41094680, PMID 41422812, PMID 41923352, PMID 41946917, PMID 42291067, PMID 42496147, PMID 42717034
2023 (6), 2014 (3), 2015 (2), 2016 (1), 2018 (1), 2019 (1), 2025 (1)